{"brief_title": "Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma", "brief_summary": "To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).", "condition": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "intervention_type": "Drug", "intervention_name": "Elsamitrucin", "criteria": "Inclusion Criteria: - Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma - at least one prior cytotoxic chemotherapy regimens - measurable disease - adequate bone marrow, liver and kidney function - ECOG PS 0-2 Exclusion Criteria: - prior treatment with elsamitrucin - prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment - HIV positive or known AIDS syndrome - uncontrolled medical disease or psychiatric condition/s", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00090090.xml"}